Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | CRHBP | P24387 | 2/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731982 | 1.00 | MAOA (0.39) | MAOAMAOBOXTRTSHRABCG2 | |
| SCHEMBL1724300 | 1.00 | MAOA (0.39) | MAOAMAOBOXTRTSHRABCG2 | |
| SCHEMBL29655819 | 1.00 | MAOA (0.39) | MAOAMAOBOXTRTSHRABCG2 | |
| SCHEMBL4502914 | 0.87 | TSHR (0.42) | MAOAMAOBOXTRTSHRABCG2 | |
| SCHEMBL9119817 | 0.87 | TSHR (0.42) | MAOAMAOBOXTRTSHRABCG2 | |
| SCHEMBL1724509 | 0.76 | MAOA (0.42) | MAOAMAOBOXTRTSHRABCG2 | |
| SCHEMBL217973 | 0.76 | — | — | |
| SCHEMBL16972815 | 0.74 | PRCP (0.33) | — | |
| SCHEMBL9116473 | 0.72 | MAOA (0.35) | MAOAMAOBOXTRTSHRABCG2 | |
| SCHEMBL9116466 | 0.71 | MAOA (0.38) | MAOAMAOBOXTRTSHRABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 736 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658141-B1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPALPHA - CD47 INTERACTION | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2022-11-16 | — | — | EP | claimed |
| CN-113861128-A | Polymerizable compound and optically anisotropic body | 江苏创拓新材料有限公司 | 2021-12-31 | — | — | CN | claimed |
| EP-1666473-B1 | CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2013-01-02 | — | — | EP | claimed |
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | claimed |
| US-8153625-B2 | Nitrogen-containing heterocyclic compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-10 | — | — | US | claimed |
| EP-1713780-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-01-18 | — | — | EP | claimed |
| JP-4806628-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| US-7759336-B2 | Nitrogen-containing heterocyclic compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-20 | — | — | US | claimed |
| US-20100159032-A1 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | PROBIODRUG AG (DE) | 2010-06-24 | — | — | US | claimed |
| EP-1620091-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-03-31 | — | — | EP | claimed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | claimed |
| US-7371871-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2008-05-13 | — | — | US | claimed |
| EP-1620091-A2 | INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2006-02-01 | — | — | EP | claimed |
| WO-2004098591-A2 | INHIBITORS OF GLUTAMINYL CYCLASE AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | PROBIODRUG AG (DE) | 2004-11-18 | — | — | WO | claimed |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2004-11-11 | — | — | US | claimed |
| EP-0918056-A1 | Herbicides | RHONE-POULENC AGRICULTURE LTD. (GB) | 1999-05-26 | — | — | EP | claimed |
| US-12630510-B2 | EP2 antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-4727924-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2026-04-22 | — | — | EP | disclosed |
| EP-0082681-A2 | Herbicidal sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-06-29 | — | — | EP | disclosed |
| US-4232115-A | MEROCYANINE, OXONOL, AND STYRYL DYES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630510-B2 | EP2 antagonist | PTGER2, PTGER1, PTGER4 | MAOA 1455/4885MAOB 2266/4885OXTR 119/4885 |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | MAOA 410/4885MAOB 939/4885OXTR 1077/4885 |
| US-20100159032-A1 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | MME, DNPEP, DPP4 | MAOA 279/4885MAOB 347/4885OXTR 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.